Table 6.
Growth outcomes in boys of the near-adult height subgroup
| Diagnosis | No.a | rhGH start | Puberty onseta | NAH | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age, y | Ht-SDS | Age, y | Ht-SDS | Prepubertal gain | Age, y | Ht-SDS | Pubertal gaina | Total gain | ||
| IGHD | 2057 | 8.6 (4.5 to 12.1) |
−2.99 (−4.44 to −2.06) |
13.0 (11.4 to 15.2) |
−1.13 (−2.37 to 0.09) |
1.86 (0.98 to 3.65) |
17.7 (16.5 to 19.9) |
−1.16 (−2.67 to 0.13) |
0.16 (−0.76 to 0.97) |
1.79 (0.72 to 3.41) |
| NSD | 108 | 9.6 (5.4 to 11.7) |
−2.90 (−3.81 to −2.13) |
13.3 (11.7 to 14.5) |
−1.15 (−2.08 to −0.40) |
1.71 (0.96 to 2.83) |
17.3 (16.3 to 18.7) |
−1.30 (−2.36 to −0.43) |
0.11 (−0.46 to 0.51) |
1.52 (0.80 to 2.58) |
| congGHD | 227 | 6.1 (1.8 to 11.4) |
−3.43 (−4.87 to −2.20) |
13.1 (11.4 to 15.2) |
−0.73 (−2.23 to 1.29) |
2.61 (1.33 to 4.76) |
18.0 (16.5 to 20.0) |
−0.93 (−2.55 to 0.95) |
0.18 (−0.89 to 0.87) |
2.42 (0.95 to 4.18) |
| CP | 127 | 8.9 (4.7 to 12.4) |
−2.20 (−3.65 to −0.40) |
13.5 (12.2 to 16.6) |
−0.06 (−1.57 to 2.16) |
1.90 (1.14 to 3.24) |
18.7 (17.0 to 20.6) |
−0.07 (−1.85 to 1.40) |
−0.08 (−0.89 to 0.79) |
1.90 (0.56 to 3.25) |
| MB | 98 | 8.6 (6.1 to 11.6) |
−1.99 (−3.12 to −0.76) |
12.2 (10.3 to 14.7) |
−0.77 (−2.12 to 0.84) |
1.21 (0.38 to 1.91) |
17.6 (16.3 to 19.8) |
−2.14 (−3.85 to −0.36) |
−1.38 (−2.09 to −0.16) |
−0.23 (−1.19 to 0.98) |
| OCT | 125 | 9.7 (7.1 to 12.3) |
−2.02 (−3.36 to −0.51) |
13.0 (11.7 to 14.8) |
−0.73 (−1.99 to 1.04) |
1.35 (0.69v2.10) |
17.7 (16.4 to 20.3) |
−0.96 (−2.99 to 0.66) |
−0.31 (−1.01 to 0.51) |
0.82 (−0.51 to 2.29) |
| ECM | 87 | 10.4 (8.1 to 12.5) |
−1.95 (−3.28 to −1.01) |
13.4 (11.9 to 15.2) |
−1.20 (−2.47 to −0.29) |
1.04 (0.28 to 1.66) |
18.0 (16.6 to 20.2) |
−1.71 (−3.62 to 0.14) |
−0.77 (−2.00 to 0.20) |
0.34 (−1.05 to 1.65) |
| ISS | 230 | 9.6 (5.7 to 12.1) |
−3.06 (−4.22 to −2.28) |
12.8 (11.6 to 15.1) |
−1.52 (−2.47 to −0.70) |
1.45 (0.77 to 2.09) |
17.7 (16.5 to 19.9) |
−1.65 (−3.25 to −0.55) |
0.01 (−0.90 to 0.76) |
1.37 (0.44 to 2.25) |
| PWS | 71 | 8.6 (5.0 to 12.0) |
−2.08 (−3.38 to −0.37) |
13.6 (11.4 to 15.0) |
0.11 (−1.71 to 1.53) |
2.27 (1.02 to 3.42) |
18.0 (16.5 to 19.8) |
−0.87 (−2.40 to 0.56) |
−1.03 (−1.42 to −0.13) |
1.31 (−0.55 to 2.46) |
| OS | 183 | 8.8 (4.1 to 11.6) |
−3.41 (−4.86 to −2.21) |
13.1 (11.6 to 14.9) |
−1.73 (−2.76 to −0.21) |
1.52 (0.80 to 3.33) |
17.8 (16.4 to 19.6) |
−2.18 (−3.63 to −0.60) |
−0.29 (−1.27 to 0.37) |
1.31 (−0.01 to 2.66) |
| SGA | 149 | 8.8 (4.4 to 11.5) |
−3.20 (−4.70 to −2.28) |
12.7 (11.5 to 14.4) |
−1.45 (−2.43 to −0.61) |
1.58 (0.87 to 2.59) |
17.2 (16.3v19.1) |
−1.88 (−3.18 to −0.61) |
−0.14 (−0.91 to 0.91) |
1.34 (0.52 to 2.61) |
| CRF | 93 | 9.6 (5.1 to 12.4) |
−3.19 (−4.59 to −1.93) |
12.7 (11.3 to 15.6) |
−2.16 (−2.85 to −0.81) |
1.48 (0.92 to 1.89) |
17.9 (16.5v20.2) |
−2.01 (−4.01 to −0.35) |
0.20 (−1.67 to 0.98) |
1.30 (−0.18 to 2.46) |
| Other | 200 | 9.0 (4.8 to 12.0) |
−3.15 (−4.73 to −1.77) |
13.3 (11.4 to 15.8) |
−1.41 (−3.28 to −0.20) |
1.75 (0.56 to 2.93) |
17.9 (16.4 to 19.6) |
−1.48 (−3.51 to 0.13) |
−0.20 (−1.33 to 1.02) |
1.51 (0.02 to 3.17) |
Data are presented as median (10th, 90th percentile) unless noted otherwise.
Abbreviations: congGHD, congenital GHD; CP, craniopharyngioma; CRF, chronic renal failure; ECM, extracranial malignancy; GHD, growth hormone deficiency; Ht-SDS, height SD score; IGHD, idiopathic GHD; ISS, idiopathic short stature; MB, medulloblastoma; NAH, near-adult height; NSD, neurosecretory dysfunction; OCT, other cranial tumors; OS, other syndromes; PWS, Prader-Willi syndrome; rhGH, recombinant human growth hormone; SGA, small for gestational age.
For puberty onset and pubertal gain at NAH, N = 703 (IGHD), 23 (NSD), 97 (congGHD), 71 (CP), 29 (MB), 31 (OCT), 20 (ECM), 83 (ISS), 16 (PWS), 64 (OS), 54 (SGA), 23 (CRF), and 56 (Other).